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Increased galectin-3 may serve as a
serologic signature of pre-rheumatoid
arthritis while markers of synovitis and
cartilage do not differ between early
undifferentiated arthritis subsets
Saida Farah Issa1* , Anne Duer2, Mikkel Østergaard3,4, Kim Hørslev-Petersen5, Merete L. Hetland3,4,
Michael Sejer Hansen6, Kirsten Junker7, Hanne M. Lindegaard1, Jakob M. Møller2 and Peter Junker1
Abstract
Background: Undifferentiated arthritis (UA) is a label applied to patients with joint complaints which cannot be
classified according to current criteria, which implies a need for precision diagnostic technologies. We studied
serum galectin-3, a proinflammatory mediator, and seromarkers of structural joint elements in patients with early,
UA and their associations with disease profile and biochemical and imaging findings.
Methods: One hundred and eleven UA patients were followed-up for at least 12 months and reclassified according
to appropriate criteria (TUDAR). At baseline, demographics and laboratory and clinical disease measures, as well as
wrist magnetic resonance imaging (MRI) synovitis, erosion, and bone marrow edema scorings, were recorded.
Galectin-3, the type IIA collagen N-terminal propeptide (PIIANP), which is a marker of regenerative cartilage
formation, and hyaluronan (HYA), which is prevalent in synovial tissue swellings, were measured by enzyme-linked
immunosorbent assay (ELISA). Receiver operating characteristic (ROC) curve analysis was carried out to assess the
discriminant capacity of galectin-3 against arthritis subsets.
Results: Galectin-3 was increased in pre-rheumatoid arthritis (RA) (4.6 μg/l, interquartile range (IQR) 3.8–5.5) versus
non-RA (4.0 μg/l, IQR 3.1–4.9; p = 0.03) and controls (3.8 μg/l, IQR 3.0–4.8; p = 0.009). PIIANP was equally depressed
in either subset (p < 0.01). Galectin-3 in non-RA and HYA in UA did not differ from healthy controls. In the entire UA
cohort, galectin-3 correlated with the MRI bone marrow edema score, while PIIANP correlated with the MRI erosion
score, and HYA with the synovitis and erosion scores. ROC curve analysis showed that baseline galectin-3
discriminated well between pre-RA and non-RA with univariate area under the curve (AUC) of 0.64 (95% confidence
interval (CI) 0.53–0.76) while AUC for galectin-3 + anti-CCP increased to 0.71 (95% CI 0.59–0.83).
Conclusions: Galectin-3 in serum was increased in patients with early UA of pre-RA origin. Cartilage remodeling
assessed by PIIANP was diminished in UA irrespective of subsequent clinical differentiation, while HYA did not differ
from controls. ROC analysis showed a potential for galectin-3 to discriminate between pre-RA and non-RA.
Trial registration: KF 11 315829. Registered 25 July 2006.
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Background
Undifferentiated arthritis (UA) is a diagnostic label
which is used to categorize patients with arthritis com-
plaints which cannot be classified according to current
criteria [1]. In a review on inception cohorts of UA pa-
tients with monoarthritis or polyarthritis, in which arth-
ritis was required to be present at inclusion, 17–32%
progressed to rheumatoid arthritis (RA) after 1 year of
follow-up [2]. Among UA patients with at least two
swollen joints enrolled in the Norfolk Arthritis Register,
25–28% were in remission after 2 years [3, 4]. Although
a number of risk factors for the development of RA have
been identified, including female gender, smoking, socio-
economic status [5], and seropositivity for antibodies to
cyclic citrullinated peptides (anti-CCP) [6] even in
asymptomatic individuals [7], it is still not possible to
predict with adequate certainty how patients with UA
will ultimately segregate into distinctive disease entities.
Several studies have investigated serological markers in-
cluding acute phase reactants, e.g., C-reactive protein
(CRP), erythrocyte sedimentation rate (ESR) [8], and in-
flammation modulators, e.g., matrix metalloproteinases
(MMPs) [9], as potential predictors for RA development
in UA. A number of prediction models for the clinical
course of UA based on disease phenotype, serologic
autoantibodies, and imaging data have been proposed in
order to improve identification of UA patients at high
risk for RA development [10, 11]. Recently, Duer-Jensen
et al. reported that bone marrow edema of the wrist and
metatarsophalangeal (MTP) joints detected by magnetic
resonance imaging (MRI) is an independent predictor of
future RA in patients with UA of short duration [12].
Combining MRI findings with clinical parameters and
autoantibodies yielded additional discriminant capacity.
In UA, there is a particular need to develop serological
disease markers reflecting distinctive metabolic and in-
flammatory disease pathways to facilitate early diagnosis
and to improve monitoring.
Several lines of evidence have implicated galectin-3 as
a pro-inflammatory mediator in RA. Synovial inflamma-
tion and structural joint damage was lower in galectin-
3–/– mice with antigen-induced arthritis as compared
with wild-type controls [13]. Ohshima et al. [14] re-
ported that galectin-3 in the serum and synovial fluid
was increased in patients with long-standing RA com-
pared with osteoarthritis (OA) and controls. These au-
thors also reported that galectin-3 mRNA and galectin-3
binding protein were expressed in particular at sites of
cartilage and bone destruction in RA joints [14]. More-
over, they found that, although galectin-3 was only
expressed in a few cells in OA synovial tissue, leucocyte
infiltration was associated with upregulation of galectin-
3 expression. In a 1-year prospective study on patients
with newly diagnosed RA before treatment initiation, we
recently reported that galectin-3 was increased, particu-
larly in anti-CCP-positive smokers. Furthermore, galectin-
3 was associated with bone marrow edema score of the
wrist at baseline and remained elevated during 12 months
of follow-up despite a targeted, synovitis-suppressive
treatment strategy [15]. Conversely, we have previ-
ously reported that a seromarker of cartilage regeneration
(type IIA collagen N-terminal propeptide (PIIANP)) is
decreased in newly diagnosed RA [16–18] while hya-
luronan (HYA), a marker of synovial swellings, is in-
creased [19, 20].
Based on these observations, and the frequent occurrence
of bone erosions in early RA before treatment [21, 22], we
hypothesized that galectin-3 in the serum may be a pre-
diagnostic signature of future RA. The aim of this investiga-
tion was to study the serum levels of galectin-3, PIIANP,
and HYA in a cohort of patients with early UA (the
TUDAR study [12]) and possible associations with disease
profile, MRI findings, and molecular markers of cartilage
remodeling and synovitis. In addition, we studied the cap-
ability of baseline galectin-3 to distinguish between pre-RA
and non-RA according to diagnostic reassessment at
1 year follow-up.
Methods
Study population
This study is based on patients with UA included in the
TUDAR protocol [12] at their first visit to rheumatology
outpatient clinics at Herlev Hospital (n = 21), Hvidovre
Hospital (n = 46), or King Christian Xth Hospital for
rheumatic diseases in Graasten (n = 44). Briefly, TUDAR
is a prospective observational study on the capability of
baseline MRI findings to predict future development of
RA according to the 1987 classification criteria [23].
From June 2006 to July 2008, 127 patients who were at
least 18 years old were included and followed for a mini-
mum of 12 months (Fig. 1). Inclusion criteria were two
or more tender and/or swollen joints among the meta-
carpophalangeal (MCP), proximal interphalangeal (PIP),
wrist, or MTP joints persisting for 6–24 months. Further
inclusion criteria were no contraindications for MRI and
the absence of a specific rheumatic disease as assessed
by a rheumatologist. Blood samples for biochemical and
experimental laboratory analyses were drawn before
initiation of drug treatment. Exclusion criteria were as
follows: allergic reaction to MRI contrasts, pregnancy or
breastfeeding, and treatment with intra-articular gluco-
corticoids before MRI examination and within 4 weeks
before inclusion. At follow-up, patients were reclassified
into RA according to the 1987 classification criteria or
non-RA, whenever possible with the addition of a spe-
cific diagnostic label according to appropriate disease
criteria.
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Control subjects
Self-reportedly healthy blood donors with an even distri-
bution according to age (decades) and gender were re-
cruited from the blood bank at Odense University
Hospital as control subjects. One hundred and twenty
subjects aged 20–65 years served as the reference popu-
lation for galectin-3 and PIIANP, respectively, and 87
blood donors aged 23–64 for HYA.
Clinical assessment
The following disease variables were recorded at inclu-
sion and at follow-up: Health Assessment Questionnaire
(HAQ), Disease Activity Score in 28 joints including
CRP (DAS28-CRP), Visual Analogue Scales (VAS (0–
100 mm) of pain, physician, and global assessment),
a 40-joint count (tender or swollen joints), serum
anti-CCP, and CRP.
Biochemical analyses
Nonfasting blood samples were centrifuged at 3000 rpm
for 10 min and were subsequently allowed to clot at
room temperature. Following centrifugation, serum was
stored at –80 °C until analysis. Serum samples from 111
of 116 patients with UA were available for analysis.
Galectin-3
Galectin-3 was measured using an enzyme-linked im-
munosorbent assay (ELISA; R&D systems, Minneapolis,
USA) according to the manufacturer’s instructions.
Galectin-3 standards, controls, and patient samples were
dispensed into microplates coated with a mouse
monoclonal antibody against Galectin-3. Upon incuba-
tion and washing, a polyclonal antibody against galectin-
3 conjugated to horseradish peroxidase was added.
Following washing to remove unbound antibody en-
zyme, a color reagent was added. The color development
was halted and absorbance was measured within 30 min
at 450 nm using an ELISA plate reader with the correc-
tion wavelength set at 540 nm. The intra- and interassay
coefficient of variation in our laboratory amounted to
3.9% and 14.9%, respectively. The reference interval for
serum galectin-3 was estimated to be 1.7–7.5 μg/l (2.5
and 97.5 percentiles) with a 95% confidence interval
(CI) of 0.8–1.9 and 6.5–10.0 for the lower and upper
limits, respectively.
PIIANP
PIIANP was quantified using ELISA (Millipore, Missouri,
USA [24]) according to the manufacturer’s instructions.
PIIANP standards, controls, and patient samples were
added to the PIIANP antibody-coated wells in the pres-
ence of a competing biotinylated PIIANP peptide. Follow-
ing incubation at room temperature for 2 h and washing,
a streptavidin-horseradish peroxidase conjugate was
added to the microplates. Upon adding a color substrate
solution, absorbance was read within 5 min at 450 nm
and 590, and the difference between absorbance units was
recorded. The intra- and interassay coefficient of variation
of PIIANP was 3.5% and 7.1%. The reference interval for
serum PIIANP was 1327–4680 μg/l (2.5 and 97.5 percen-
tiles) with a 95% CI of 894–1391 and 4234–4874 for the
lower and upper limits, respectively.
Fig. 1 Flowchart showing patient disposition adapted from Duer-Jensen et al. [12]. RA rheumatoid arthritis
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HYA
HYA was measured by ELISA (Corgenix, Colorado,
USA) according to the manufacturer’s instructions. The
assay used microwells coated with a highly specific hya-
luronic acid binding protein (HABP). HYA standards,
controls, and patient samples were dispensed into the
microwells. Upon incubation and washing, an enzyme-
conjugated version of HABP was added to detect HYA
in the samples. A color reagent was added and absorb-
ance was measured within 30 min at 450 nm. The intra-
and interassay coefficient of variation of HYA amounted
to 3.6% and 6.1%, respectively. The reference interval for
HYA was 2.4–77.0 μg/l (2.5 and 97.5 percentiles) with a
95% CI of 2.3–5.3 and 44.0–81.1 for the lower and upper
limits, respectively.
Anti-CCP antibodies and serum CRP
Anti-CCP antibodies and serum CRP (mg/l) were mea-
sured according to standard laboratory procedures ap-
plied in the participating departments, with cut-off
values of 5 U/ml and 5 mg/l, respectively.
MRI
MRI of the dominant extremity (wrist, MCP, PIP, and
MTP) was obtained before and after intravenous injection
with gadolinium-based contrast (0.2 ml/kg; Dotarem,
Guerbet, Roissy, France) within 2 weeks from inclusion.
An MRI-experienced rheumatologist evaluated the images
for RA pathologies according to the OMERACT (Out-
come Measures in Rheumatology) MRI scoring system
(RAMRIS) [25], while an experienced radiologist evalu-
ated the images for other pathologies. All MRI evaluations
were performed separately, and evaluators were blinded to
clinical data. The MRI measures included evaluation of
bone erosion score, synovitis score, and bone marrow
edema score. Synovitis was scored from 0–3 in three
different areas of the wrist and in each MCP, PIP, and
MTP joint. Bone marrow edema was scored from 0–3 and
bone erosion from 0–10 in each bone.
Statistical analyses
Descriptive statistics concerning demographics, disease,
and imaging variables for the groups are presented as
medians and interquartile ranges (IQRs). The Mann-
Whitney test was applied for comparison between
groups. Univariate regression analyses were performed
to assess correlations between galectin-3, PIIANP, or
HYA and clinical and imaging variables. Subsequently,
variables with a p value ≤0.20 were included in multiple
regression analyses. Logistic regression was performed
for the assessment of the predictive value of galectin-3
with regard to future RA development (diagnostic cri-
teria fulfilled, yes/no) with adjustment for previously
proposed risk factors, including age, gender, CRP,
swollen joint count, tender joint count, anti-CCP [26],
and bone marrow edema [12]. Finally, analysis of re-
ceiver operating characteristic (ROC) curves was per-
formed in order to assess the capability of baseline
galectin-3 to discriminate between pre-RA and non-RA
in patients with UA at follow-up. P values ≤0.05 were
considered statistically significant. The statistical analysis
was performed using STATA version 13.
Results
One hundred and sixteen patients participated after ex-
clusion of patients with other rheumatic diseases at
baseline, an incomplete dataset, or lack of follow-up.
Among the 111 patients with available baseline sera, 23
were subsequently diagnosed with RA (pre-RA), while
88 had persistent UA, remitted, or had developed alter-
native classifiable conditions (non-RA), e.g., OA or
psoriatic arthritis (Fig. 1). The median follow-up time
was 17 months (12–23 months) [12]. At baseline, the
pre-RA patients and non-RA group were comparable
with regard to age and gender distribution and symptom
duration. However, patients classified as having RA at
follow-up had overall higher CRP (p < 0.01), more swol-
len (p = 0.03) and tender joints (p = 0.05), as well as
higher VAS, HAQ, and DAS28-CRP scores at the time
of inclusion (Table 1).
When stratifying according to MRI findings in the two
UA subgroups, pre-RA had higher wrist MRI synovitis
scores (p < 0.01), bone marrow edema scores (p < 0.01)
and erosion scores (p = 0.01). Regression analyses with
either MRI MTP or wrist scores or MRI wrist +MTP
scores yielded similar results. Accordingly, only MRI
wrist data were included.
Outliers were identified based on z scores and in-
cluded in the calculations. Concerning galectin-3, three
outliers in the UA study population and two in the con-
trols were identified. One PIIANP outlier was found in
both the UA and control population. Similarly, two and
five HYA outliers were identified in the UA and control
population, respectively. Baseline serum levels of
galectin-3, PIIANP, and HYA are presented in Table 2.
Galectin-3
Galectin-3 was increased in the pre-RA subset (4.6 μg/l,
IQR 3.8–5.5) compared with healthy controls (3.8 μg/l,
IQR 3.0–4.8; p = 0.009) and non-RA (4.0 μg/l, IQR 3.1–
4.9; p = 0.03).
When combining non-RA and pre-RA subsets,
galectin-3 was slightly, but insignificantly, increased
compared with healthy controls (p = 0.2). Galectin-3 in
non-RA did not differ from healthy controls (p = 0.56).
There was no significant difference in galectin-3 levels
after stratification according to anti-CCP in the entire
UA population and the pre-RA subset.
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Univariate regression analyses including core disease
measures and MRI findings showed that galectin-3 cor-
related positively with CRP, VAS pain, and MRI bone
marrow edema. However, in the multiple regression
model applied to the entire UA study population, CRP,
VAS pain, and MRI bone marrow edema came out as
nonsignificant.
Only imaging variables were included in regression ana-
lyses of pre-RA and non-RA subsets due to the small popu-
lation samples after stratification. Following univariate
regression analysis, galectin-3 in pre-RA did not correlate
with MRI synovitis score, bone marrow edema score, or
erosion score. Conversely, in non-RA, galectin-3 correlated
positively with MRI bone marrow edema score (p = 0.02),
also after adjustment for age and gender (p = 0.05).
The type IIA collagen N-terminal propeptide
PIIANP was significantly lower in the entire UA group
(1800 μg/l, IQR 1439–2252) versus healthy control sub-
jects (2189 μg/l, IQR 1788–2712; p < 0.0001; Fig. 2).
PIIANP levels did not differ significantly between anti-
CCP subsets in the entire UA study population. PIIANP
was equally depressed in pre-RA (1704 μg/l, IQR 1439–
2105) and non-RA (1801 μg/l, IQR 1436–2260) as com-
pared to healthy controls (p < 0.01).
In the univariate analysis, swollen joint count, ten-
der joint count, VAS global, and MRI erosion score
emerged as statistically significant. PIIANP correlated
inversely with VAS global score (p = 0.05) upon
multivariate regression in the complete UA study
population.
Table 1 Baseline demographic, clinical, and laboratory characteristics of patients with undifferentiated arthritis (UA)
Characteristic Total UA
(n = 111)
Pre-RA
(n = 23)
Non-RA
(n = 88)
p value
(pre-RA vs non- RA)
Sex (M/F) 25/86 5/18 20/68 0.92
Age (years) 48 (41–57) 50 (44–59) 47 (39–56) 0.28
Anti-CCP (positive/negative) 15/96 8/15 7/81 <0.001
Symptom duration (months) 6 (4–12) 5 (4–12) 7 (4.5–12) 0.50
C-reactive protein (mg/l) 4 (3–8) 8 (4–14) 4 (3–6) <0.01
Swollen Joint Count (40) 0 (0–2) 1 (0–2) 0 (0–2) 0.03
Tender Joint Count (40) 9 (5–20) 15 (5–27) 8 (4.5–17) 0.05
Visual Analogue Scale – Doctor (0–100 mm) 12 (5–24) 24 (18–30) 9 (3–19) <0.001
Visual Analogue Scale – Pain (0–100 mm) 36 (17–54) 54 (21–69) 34 (17–51) 0.01
Visual Analogue Scale – Global (0–100 mm) 41 (20–59) 60 (40–71) 36 (15–55) <0.01
DAS28-CRP 3.6 (2.9–4.3) 4.1 (3.6–5.1) 3.5 (2.7–4.2) <0.01
HAQ score (0–3) 0.4 (0–1) 0.75 (0–1.3) 0.37 (0–0.75) 0.05
MRI wrist synovitis score 3 (2–5) 5 (3.5–5.5) 3 (2–5) <0.01
MRI wrist erosion score 3 (1–5) 4 (2–5.5) 2 (0–4) 0.01
MRI wrist bone marrow edema score 0 (0–1) 1 (0–2) 0 (0–0) <0.01
Results are presented as medians (interquartile range) unless otherwise stated
Significant p values are indicated in bold typeface
Anti-CCP antibodies to cyclic citrullinated peptides, DAS28-CRP Disease Activity Score in 28 joints including C-reactive peptide, HAQ Health Assessment Questionnaire,
MRI magnetic resonance imaging, RA rheumatoid arthritis
Table 2 Baseline levels of galectin-3, hyaluronan, and the type IIA collagen N-terminal propeptide
Marker Reference interval Total UA
(n = 111)
Pre-RA
(n = 23)
Non-RA
(n = 88)
Controls
(n= 120 or 87)
p value
(pre-RA vs
non-RA)
p value
(pre-RA vs controls)
p value
(non-RA vs controls)
Galectin-3 (μg/l) 1.65–7.54 4.1
(3.3–5.2)
4.6
(3.8–5.5)
4.0
(3.1–4.9)
3.8
(3.0–4.8)
0.03 0.009 0.56
Hyaluronan (μg/ml) 2.42–77.02 15.1
(8.5–30)
19.4
(8.5–30)
14.75
(8.6–30)
17.4
(10–25.8)
0.64 0.75 0.61
PIIANP (μg/l) 1327–4680 1800
(1439–2252)
1704
(1439–2105)
1801
(1436–2260)
2189
(1788–2712)
0.75 0.004 0.0001
Results are presented as medians (interquartile range) unless otherwise indicated
Significant p values are indicated in bold typeface
PIIANP type IIA collagen N-terminal propeptide, RA rheumatoid arthritis, UA undifferentiated arthritis
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PIIANP correlated positively with MRI erosion score
by univariate analysis (p = 0.03) in non-RA although
this was nonsignificant following adjustment for age
and gender (p = 0.08). In pre-RA alone, PIIANP cor-
relations with MRI synovitis score, bone marrow
edema score, or erosion score did not reach statistical
significance.
Hyaluronan
HYA did not differ between patients with UA (15.1 μg/l,
IQR 8.5–29.9) and controls (17.4 μg/l, IQR 10–25.8;
p = 0.75). Similarly, HYA in pre-RA (p = 0.87) and non-RA
(p = 0.61) did not differ significantly compared to healthy
controls. In the entire UA study population and the two
subsets, HYA was higher in the anti-CCP negative group
compared with the positive group, although this was not
statistically significant.
Anti-CCP, CRP, tender joint count, DAS28-CRP,
MRI erosion score, MRI bone marrow edema score,
and MRI synovitis score emerged as significant in
univariate regression analyses with HYA as a
dependent variable. HYA correlated inversely with
anti-CCP positivity (p = 0.02) using multivariate
regression.
HYA in the pre-RA subset did not correlate with MRI
synovitis score, bone marrow edema score, or erosion
score following univariate regression analysis. Con-
versely, all three MRI scores (synovitis score, p = 0.001;
erosion score, p = 0.18; and bone marrow edema score,
p = 0.10) emerged as significant by univariate analysis of
HYA in non-RA, but did not attain statistical signifi-
cance after multivariate regression analysis.
Table 3 summarizes the univariate and multivariate
analyses in the entire UA study population.
Prediction of final diagnosis
The predictive capacity of baseline galectin-3 was stud-
ied with logistic regression with adjustment for known
independent predictors of developing RA (odds ratio
1.54, p = 0.05). Thus one-unit increase in serum
galectin-3 increased the odds of developing RA by a fac-
tor of 1.54. In addition, the predictive value of baseline
galectin-3 regarding future development of RA versus
non-RA or healthy controls was also studied using uni-
variate ROC analysis. Univariate area under curve
(AUC) for galectin-3 was 0.64 (95% CI 0.53–0.76) for
discriminating between pre-RA and non-RA. The corre-
sponding figure for anti-CCP was 0.63 (0.53–0.74), while
AUC for the combination of galectin-3 and anti-CCP in-
creased to 0.71 (0.59–0.83; Fig. 3). Similarly, univariate
AUC of MRI bone marrow edema score resulted in an
AUC of 0.66 (0.54–0.78), while the combination of
galectin-3 and bone marrow edema of the wrist yielded
an AUC of 0.73 (0.63–0.83), which was not statistically
different from galectin-3 + anti-CCP (p = 0.78). The AUC
of galectin-3 + anti-CCP + bone marrow edema score
was 0.74 (0.64–0.85).
Discussion
Patients presenting with joint complaints of uncertain
origin are a common source of concern to clinicians
with regard to diagnostic delay and missed therapeutic
opportunities. In this first study on galectin-3 and se-
lected seromarkers of joint tissue remodeling in patients
with early, undifferentiated arthritis, we report that
galectin-3 in serum was increased in pre-RA versus non-
RA and a healthy control population. PIIANP, a marker
of regenerative cartilage collagen IIA synthesis, was
equally depressed in pre- and non-RA, while HYA was
in the normal range in either subset. In the entire UA
cohort, galectin-3 correlated positively with MRI bone
marrow edema score, whereas PIIANP was associated
with MRI erosion score and HYA with both MRI syno-
vitis and erosion scores. Galectin-3 discriminated well
between pre-RA and non-RA.
The present finding of increased galectin-3 levels in
serum of patients with UA who subsequently developed
RA as compared with other UA subsets adds to the
Fig. 2 Galectin-3, PIIANP, and hyaluronan levels (median and interquartile range) in pre-RA, non-RA, and healthy subjects. Intergroup comparison
between subsets of patients with early, undifferentiated arthritis and healthy controls was carried out using the Mann-Whitney test. PIIANP N-terminal
propeptide of type IIA collagen, RA rheumatoid arthritis
Issa et al. Arthritis Research & Therapy  (2017) 19:80 Page 6 of 10
experimental and clinical evidence that galectin-3 plays
a critical role in RA development, e.g., by regulating RA
synovial fibroblast functions. Thus, galectin-3 induces
distinctive pro-inflammatory cytokine and chemokine
expression profiles in RA synovial fibroblasts as com-
pared with dermal fibroblasts [27]. In addition, Ohshima
et al. reported that galectin-3 and its binding protein is
overexpressed in the RA synovial membrane, particularly
at the invading pannus front, and that galectin-3 in the
serum and synovial fluid is increased in patients with
long-standing RA compared with osteoarthritis and
healthy controls [14]. Recently, in a cohort of patients
Fig. 3 Capability of baseline galectin-3 to predict RA development in patients initially classified with UA. ROC curve analysis was used to assess
the ability of galectin-3 alone (a) or in combination with anti-CCP (b) to distinguish between UA patients who will and those who will not develop RA
within 12–23 months follow-up. UA: undifferentiated arthritis.. Anti-CCP antibodies to cyclic citrullinated peptides, AUC area under curve
Table 3 Univariate and multivariate analyses of galectin-3, PIIANP, and hyaluronan against biochemical, clinical, and
imaging findings
Square root of galectin-3 (n = 111) Log PIIANP (n = 111) Log hyaluronan (n = 111)
Variable Beta
coefficient
95% CI p value Beta
coefficient
95% CI p value Beta
coefficient
95% CI p value
Univariate regression
Anti-CCP – – –0.34 –0.87 to 0.18 0.20
C-reactive protein 0.01 0.005 to 0.02 0.002 – 0.02 (0.002 to 0.04) 0.05
Swollen Joint count – –0.08 –0.14 to –0.02 0.006 –
Tender Joint count – 0.009 –0.003 to 0.02 0.15 –0.02 (–0.04 to –0.001) 0.04
VAS – Doctor – – –
VAS – Pain 0.003 –0.0006 to 0.007 0.10 – –
VAS – Global – –0.002 –0.005 to 0.0008 0.15 –
DAS28-CRP – – –0.19 –0.36 to –0.02 0.03
HAQ score – – –
MRI synovitis score – – 0.11 0.02 to 0.20 0.02
MRI erosion score – 0.04 0.003 to 0.07 0.03 0.05 (–0.01 to 0.11) 0.11
MRI bone marrow
edema score
0.02 –0.004 to 0.04 0.11 – –
Multivariate regression
Anti-CCP – – –0.59 –1.08 to –0.09 0.02
VAS – Global – –0.003 –0.007 to –0.00002 0.05 –
Dashes represent nonsignificant results. Results with p values ≤0.20 and ≤0.05 were considered significant in univariate and multivariate regression
analyses, respectively
Anti-CCP antibodies to cyclic citrullinated peptides, CI confidence interval, DAS28-CRP Disease Activity Score in 28 joints including C-reactive peptide, HAQ Health
Assessment Questionnaire, MRI magnetic resonance imaging, PIIANP type IIA collagen N-terminal propeptide, VAS visual analogue scale
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with early, untreated RA we found persistently increased
levels of circulating galectin-3 in serum despite subse-
quent introduction of a targeted synovitis suppressive
treatment protocol [15]. Notably, baseline galectin-3 did
not correlate with clinical disease activity measures such
as tender and swollen joint counts or DAS28-CRP, but
correlated positively with MRI erosion and anti-CCP,
which is a strong predictor of erosive progression in RA
[28]. In the present study on early UA, galectin-3 corre-
lated with CRP but not with joint counts or DAS28-CRP
score (Table 3). Galectin-3 also correlated with bone
marrow edema, however, reaching statistical significance
in the non-RA subset only. This finding may reflect that
joint degradative pathways are shared at early stages of
different arthritides. Also, the relatively small number of
pre-RA patients should be considered. Altogether, these
observations concord with evidence from studies using
modern imaging technologies that erosive damage in RA
may proceed in the absence of clinically detectable syno-
vitis [29–31]. Recently, this has also been reported to
take place in joints with persistent bone marrow edema
[32]. The abovementioned experimental and clinical
studies and the association between increased galectin-3
levels in the serum and bone marrow edema score in
UA and early RA independent of current synovitis sug-
gest that galectin-3 may be an important mediator of
joint destruction in arthritis.
Galectin-3 expression by RA synovial fibroblasts is
stimulated by binding to cartilage oligomeric matrix pro-
tein (COMP), a structural cartilage matrix protein be-
longing to the thrombospondin family [33]. In order to
characterize possible links between the increased
galectin-3 levels and cartilage and synovial tissue remod-
eling, we performed additional measurements of sero-
logical markers of cartilage collagen regeneration
(PIIANP) [16–18] and synovitis-related swellings (hya-
luronan) [20]. PIIANP was equally depressed in pre-RA
and non-RA and correlated with MRI erosion score in
the entire UA population, but not with the occurrence
of anti-CCP (Table 3). Previously, we reported that cir-
culating PIIANP was decreased in a large cohort of
newly diagnosed, treatment-naive patients with RA clas-
sified according to the 1987 criteria, particularly in the
anti-CCP subset. In that study, PIIANP did not associate
with disease activity, but correlated inversely with anti-
CCP titer [18] suggesting a chondrocyte suppressive ef-
fect by these autoantibodies [34–36]. More recently, we
reported that PIIANP was increased in active, untreated
axial spondyloarthritis, particularly in those testing posi-
tive for human leukocyte antigen (HLA)-B27, probably
reflecting enhanced enthesopathic tissue proliferation in
axial joint disease [37]. In the present study on UA,
PIIANP was not associated with anti-CCP status, which
may be due to the small sample size of anti-CCP-
positive patients. However, as in early RA, PIIANP was
decreased in the present early UA cohort regardless of
the follow-up diagnosis, suggesting that early synovitis of
any origin may reduce cartilage regeneration and repair.
This is supported by the correlation between decreased
baseline PIIANP and MRI erosion score. The inverse
correlation between PIIANP and VAS global assessment
score probably reflects the link between deep cartilage
remodeling and disease activity in UA.
HYA is a well-documented seromarker of synovitis
mass in RA [19, 20]. Although the swollen joint count in
the entire UA population and the two major subsets was
low, wrist MRI synovitis scores ranged between 2–5,
3.5–5.5, and 2–5, respectively. This indicates that a
threshold volume of synovial inflammation must be
exceeded to be reflected in the circulation and that sub-
clinical synovitis may go unnoticed if tracked by HYA
recordings only. Interestingly, HYA correlated inversely
with anti-CCP positivity using multivariate regression
analysis (Table 3). The unanticipated higher levels of
HYA in anti-CCP-negative UA patients may pertain to
the report by van Oosterhout et al. that the synovial lin-
ing layer is thicker in anti-CCP-negative as compared
with anti-CCP-positive RA patients [38].
The ability of galectin-3 to discriminate between pre-
RA and non-RA was calculated by ROC analysis (Fig. 2).
Galectin-3 alone distinguished fairly well between UA
patients who later developed RA and those who did not,
with an AUC of 0.64 and, for anti-CCP alone, 0.63.
When combining galectin-3 and anti-CCP, AUC in-
creased to 0.71, and with the further addition of bone
marrow edema to 0.74. These quite similar figures indi-
cate that galectin-3 may qualify as a future serological
marker for prediction of RA development in UA.
Some issues of concern should be addressed. In this study
we adopted the 1987 criteria for RA classification [23]. This
implies that some individuals would have been categorized
as RA according to the 2010 criteria [39], thereby qualifying
for exclusion from the study. This potential source of
categorization error is underscored by the finding that 7/81
of the non-RA participants tested positive for anti-CCP. On
the other hand, this is a study aiming at identifying bio-
logically plausible new seromarkers for clinical use. It was
therefore essential to apply these candidate markers to pa-
tient subsets diagnosed with optimal specificity. Some pa-
tients with UA may only differentiate into RA beyond
12 months [2]. The number of anti-CCP-positive patients
was rather small. Accordingly, regression subanalysis with
stratification into sero-negatives and sero-positives was not
feasible. Smoking status was not available. Major strengths
include the collection of a large sample of carefully charac-
terized patients with UA and complete follow-up at 1 year,
which allows for separation of patients who did from those
who did not develop RA.
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Conclusions
Galectin-3 is increased at the pre-diagnostic stage of RA
versus non-RA, and discriminates well between UA pa-
tients who will and those who will not develop RA
within 12–23 months. UA is associated with a decreased
cartilage collagen regenerative response irrespective of
synovitis origin.
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